1. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19;Owen;Science,2021
2. Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89 % in Interim Analysis of Phase 2/3 EPIC-HR Study,2021
3. Pfizer Announces Additional Phase2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death,2021
4. Darunavir: a review of its use in the management of HIV infection in adults;McKeage;Drugs,2009
5. Pregnancy and neonatal outcomes in COVID-19: study protocol for a global registry of women with suspected or confirmed SARS-CoV-2 infection in pregnancy and their neonates, understanding natural history to guide treatment and prevention;Banerjee;BMJ Open,2021